The findings may help millions of doctors work with their patients to determine the right choice for them in a sea of options ...

If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit ...

According to new research, this centuries-old beverage supports long-term brain health by dialing down inflammation and ...

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

noradrenaline and dopamine. “There are more than 30 antidepressants across different classes such as SSRIs, SNRIs, NDRIs, ...

Of the large percentage of antidepressant takers who experience sexual side effects, there is a small percentage for ... many people opt for or switch to bupropion, a norepinephrine-dopamine reuptake ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

This approval represents another step in Sunshine Biopharma’s strategic expansion into the generic pharmaceuticals market. According to data cited by the company, global Domperidone sales are ...

With U.S. diagnoses of Parkinson's expected to reach 1.2 million by 2030, research is in full swing, and treatments ...

Weekly intramuscular injections of rotigotine extended-release microspheres are linked to significant symptom improvement in ...